微粒化非诺贝特与辛伐他汀治疗糖尿病合并高脂血症的比较

Micronised fenofibrate vs simvastatin in treating hyperlipidemia in NIDDM patients

目的 :观察微粒化非诺贝特与辛伐他汀治疗 2型糖尿病 (NIDDM )合并高脂血症的疗效。方法 :4 0例 (男性 2 2例 ,女性 18例 ,年龄 55a±s 8a)NIDDM病人用微粒化非诺贝特胶囊 0 .2 g ,po ,qd× 8wk。另 38例 (男性 2 1例 ,女性 17例 ,年龄 54a± 9a)NIDDM病人用辛伐他汀片 5mg ,po ,qd× 8wk。结果 :非诺贝特组依次降低TC ,TG ,LDL C为18% ,4 6% ,2 2 %及升高HDL C 2 0 % ;辛伐他汀组依次下降 2 5% ,2 8% ,2 3%及升高 18%。非诺贝特组较辛伐他汀组TG下降更显著 (P <0 .0 1)。结论 :微粒化非诺贝特是NIDDM合并高脂血症病人有效的调脂药物 。

AIM: To compare the effect of micronised fenofibrate and simvastatin in the treatment of non insulin dependent diabetes mellitus (NIDDM) patients with hyperlipidemia. METHODS: Forty NIDDM patients (M 22, F 18; age 55 a± s 8 a) received micronised fenofibrate 0.2 g, po , qd, for 8 wk. The other 38 NIDDM patients (M 21, F 17; age 54 a±9 a) received simvastatin 5 mg, po , qd, for 8 wk. RESULTS: Both drugs were effective in lowering total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL C) and increasing high density lipoprotein cholesterol (HDL C). In micronised fenofibrate group TC,TG, LDL C were decreased 18%,46%,22%, respectively, HDL C was increased 20%. Simvastatin group, TC,TG,LDL C were decreased 25%,28%,23%, respectively, HDL C was increased 18%. The levels of serum TG were decreased more sigificantly in fenofibrate group than in simvastatin group. ( P <0.01). CONCLUSION: Micronised fenofibrate is an effective antilipidemic drug in treating NIDDM patients with hyperlipidemia. It is more effective in lowering TG than simvastatin.